Company / R&D Expense
AbbVie R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$9.1B
FY2025
5-year range
$6.5B / $12.8B
FY2021-FY2025
Trend
-28.9%
vs FY2024
Sector context
#5 of 209
Health Care
What the data says
Among 209 Health Care companies, AbbVie is in the top 2% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $4.4B in FY2016 to $12.8B in FY2024.
Based on SEC 10-K filings.
$9.1B in FY2025 with a 5-year CAGR of +7.4%. Top quartile in the Health Care sector.
Improved from $7.7B to $9.1B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +11.8%
- 5-Year CAGR
- +7.4%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 209This company $9.1B Sector average $647.6M
▼
+1304.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.4%, indicating consistent growth.
- In FY2025, r&d expense decreased 28.9% year-over-year.
- Ranks #5 out of 209 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.1B | -28.9% |
| FY2024 | $12.8B | +66.7% |
| FY2023 | $7.7B | +17.9% |
| FY2022 | $6.5B | -6.0% |
| FY2021 | $6.9B | +8.5% |
| FY2020 | $6.4B | -0.4% |
| FY2019 | $6.4B | -38.0% |
| FY2018 | $10.3B | +106.3% |
| FY2017 | $5.0B | +14.2% |
| FY2016 | $4.4B | +2.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026